Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Zhong Ji Longevity Science Group Limited ( (HK:0767) ).
Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular regarding its planned major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited through the issue of convertible notes. The circular, which will include details of the deal, independent advice and financial information, is now expected to be dispatched on or before 29 May 2026, potentially extending the timetable for shareholder approval and execution of this strategic life-science investment.
The postponement reflects additional time needed to prepare and finalise the required disclosures, underscoring the complexity and regulatory sensitivity of the transaction under Hong Kong listing rules. While the delay may briefly defer clarity for investors and other stakeholders, the acquisition remains positioned as a key step in strengthening the group’s exposure to advanced cell laboratory capabilities and the broader longevity-focused healthcare market.
More about Zhong Ji Longevity Science Group Limited
Zhong Ji Longevity Science Group Limited, incorporated in Bermuda and listed in Hong Kong, operates in the longevity science and related healthcare sector. The group focuses on investments and transactions connected to advanced biomedical and cell laboratory businesses, aligning its market strategy with emerging life-science and longevity technologies in Asia.
Average Trading Volume: 506,359
Technical Sentiment Signal: Sell
Current Market Cap: HK$296M
See more insights into 0767 stock on TipRanks’ Stock Analysis page.